Tildrakizumab was approved by FDA in 2018 for
High-Yield Explanation
Tildrakizumab was approved by FDA in 2018 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Related Pharmacology MCQs
Which of the following is glucocoicoid synthesis inhibitor?
General
At a high altitude of 3000 m, a person complains of breathlessness. All of the following can...
General
All of the following drugs act on cell membrane except:
General
A non-competitive inhibitor of an enzyme?
General
Which of the following is a phase I metabolic reaction?
General